Some FDA staff are contemplating leaving amid speculation that Robert F. Kennedy Jr. could play a health role in the incoming Trump administration, according to current and former officials. While turnover is typical with a new administration, concerns this time extend beyond Trump to Kennedy, a vaccine skeptic who has pledged to overhaul federal health agencies.
Kennedy told NBC News he would push for changes, citing departments like the FDA’s nutrition sector as needing elimination. Trump, for his part, has said he’d let Kennedy “go wild on health.” Staff anxiety stems from potential policy disruptions and rumored post-employment restrictions, like ending the “revolving door” between agency roles and lobbying.
During Trump’s first term, FDA staff initially worried but largely stayed, implementing priorities like faster drug approvals. Now, however, more employees are proactively considering their options, one official said, adding that “dozens” may be exploring departures. Some staff eligible for retirement might view this as an ideal exit point.
FDA Commissioner Robert Califf expressed disappointment with the election results, acknowledging uncertainty about the agency’s future. He noted the administration’s intent to “change a lot of things” depends on leadership appointments and policies.
While chatter about resignations abounds, no significant departures have been confirmed. Kennedy might take on a role with minimal impact on FDA operations, such as leading a chronic disease initiative. The agency, which employs over 18,000 people, did not comment on potential staff turnover.
Also read: US Border Chief Warns Canada Could Be ‘Gateway for Terrorists
